Oxilorphan

Oxilorphan

Systematic (IUPAC) name
(-)-17-(cyclopropylmethyl)-morphinan-3,14-diol
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	42281-59-4
ATC code	None
PubChem	CID 5361090
ChemSpider	16736680 Y
UNII	9Y9J2J74TO Y
KEGG	D05299 Y
Chemical data
Formula	C20H27NO2
Mol. mass	313.44 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C20H27NO2/c22-16-6-5-15-11-18-20(23)8-2-1-7-19(20,17(15)12-16)9-10-21(18)13-14-3-4-14/h5-6,12,14,18,22-23H,1-4,7-11,13H2/t18-,19+,20-/m1/s1 Y Key:STBZIDOIKQNFCQ-HSALFYBXSA-N Y
Y(what is this?)  (verify)

Oxilorphan is an opioid antagonist from the morphinan family of drugs.

Oxilorphan is a non-selective opioid which is a μ antagonist but a κ partial agonist. It has similar effects to naloxone, and around the same potency as an antagonist.^[1]

Oxilorphan has some weak partial agonist effects^[2] and can produce hallucinogenic effects at high doses, suggesting some kappa opioid agonist action.^[3] It was trialled for the treatment of opiate addiction, but was not developed commercially.^[4]

See also

• Morphinan
• Dextrallorphan

References

1. ^ Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Journal of Pharmacology and Experimental Therapeutics. 1975 Apr;193(1):23-34.
2. ^ Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. Journal of Clinical Pharmacology. 1976 Apr;16(4):183-7.
3. ^ Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. European Journal of Pharmacology. 1983 Jan 21;86(3-4):467-70.
4. ^ Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. Drug and Alcohol Dependence. 1976 Jun;1(5):329-37.